MARKET

VKTX

VKTX

Viking Therapeutics Inc
NASDAQ
31.71
+0.01
+0.03%
After Hours: 31.57 -0.14 -0.44% 19:57 05/14 EDT
OPEN
31.78
PREV CLOSE
31.70
HIGH
32.02
LOW
30.82
VOLUME
1.43M
TURNOVER
--
52 WEEK HIGH
43.15
52 WEEK LOW
22.96
MARKET CAP
3.68B
P/E (TTM)
-7.6487
1D
5D
1M
3M
1Y
5Y
1D
This Hot Weight-Loss Drug Stock May Have a Surprise Challenger
Barchart · 10h ago
Corbus Pharmaceuticals Holdings Inc. Stock Advances 6.3%, Outperforms Peers
Dow Jones · 1d ago
Viking Therapeutics’ VK2735 demonstrates wieght loss in Phase 2 trial
TipRanks · 2d ago
Viking Therapeutics Presents Additional Data From Phase 2 VENTURE-Oral Dosing Trial Evaluating Oral Tablet Formulation Of VK2735 At ECO In Istanbul, Türkiye
Benzinga · 2d ago
Viking says oral VK2735 cuts weight up to 12.2% in Phase 2 trial
PUBT · 2d ago
VIKING THERAPEUTICS PRESENTS DATA FROM ITS 13-WEEK PHASE 2 VENTURE-ORAL DOSING TRIAL OF VK2735 AT EUROPEAN CONGRESS ON OBESITY (ECO) 2026
Reuters · 2d ago
Weekly Report: what happened at VKTX last week (0504-0508)?
Weekly Report · 3d ago
Viking Therapeutics: Market Betting On Big Upside Through 2030
Seeking Alpha · 05/05 16:00
More
About VKTX
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is focused on the development of therapies for the treatment of metabolic and endocrine disorders. Its clinical programs include VK2735, a novel dual agonist of the glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide receptors for the potential treatment of various metabolic disorders. It is evaluating an oral formulation of VK2735 in a Phase II trial. It is also developing VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders. Its newest program is evaluating a series of internally developed dual amylin and calcitonin receptor agonists for the treatment of obesity and other metabolic disorders. In the rare disease space, it is developing VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the potential treatment of X-linked adrenoleukodystrophy.

Webull offers Viking Therapeutics Inc stock information, including NASDAQ: VKTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VKTX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading VKTX stock methods without spending real money on the virtual paper trading platform.